Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

TRA-2P TIMI 50, 2012 - vorapaxar vs placebo

CHARISMA, 2006 - clopidogrel + aspirin vs aspirin

Murphy, 2003 - roxifiban vs placebo

JAMIS, 1999 - aspirin vs placebo

CAPRIE, 1996 - clopidogrel vs aspirin

CAPRIE, 1996 - clopidogrel vs aspirin

SAPAT, 1992 - aspirin vs placebo

PARIS-II, 1986 - dipyridamol + aspirin vs placebo

Berglund, 1985 - ticlopidine vs placebo

AMIS, 1980 - aspirin vs placebo

PARIS, 1980 - dipyridamol + aspirin vs aspirin

PARIS, 1980 - aspirin vs placebo

GAMIS, 1980 - aspirin vs placebo

PARIS, 1980 - dipyridamol + aspirin vs placebo

Vogel, 1979 - aspirin vs placebo

Cardiff II, 1979 - aspirin vs placebo

CDPA, 1976 - aspirin vs placebo

Cardiff I, 1974 - aspirin vs placebo

Igloe, 1970 - dipyridamol vs placebo

Atlanta (Sbar), 1967 - dipyridamol vs control

Wirecki, 1967 - dipyridamol vs control

Becker, 1967 - dipyridamol vs control

Neumann, 1964 - dipyridamol vs placebo

Leiberman, 1964 - dipyridamol vs placebo

Kinsella, 1962 - dipyridamol vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All stable angina clinical trials
  • All coronary artery disease clinical trials
  • All clinical trials of death and events prevention
  • All clinical trials of aspirin
  •  

    SAPAT study, 1992

    download pdf: aspirin | antithrombotics for stable angina

    Treatments

    Studied treatment aspirin 75 mg daily
    Control treatment placebo
    Concomittant treatment sotalol for control of symptoms

    Patients

    Patients patients with stable chronic angina pectoris

    Method and design

    Randomized effectives 1009 / 1026 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 50 months
    Geographic area Sweden
    Hypothesis Superiority
    Primary endpoint myocardial infarction and sudden death
    Withdrawals (T1/T0) 109 (10.8%) / 100 (9.75%)


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Non fatal MI

    40 / 1009
    61 / 1026
    0,67 [0,45;0,98]

    Cardiovascular death

    53 / 1009
    71 / 1026
    0,76 [0,54;1,07]

    Non vascular death

    18 / 1009
    11 / 1026
    classic 1,66 [0,79;3,51]

    Non fatal stroke

    21 / 1009
    27 / 1026
    0,79 [0,45;1,39]

    cardiovascular events

    111 / 1009
    159 / 1026
    0,71 [0,57;0,89]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Non fatal MI 40 / 1009 (4,0%) 61 / 1026 (5,9%) 0,67 [0,45;0,98]  
    Cardiovascular death 53 / 1009 (5,3%) 71 / 1026 (6,9%) 0,76 [0,54;1,07]  
    Non vascular death 18 / 1009 (1,8%) 11 / 1026 (1,1%) 1,66 [0,79;3,51]  
    Non fatal stroke 21 / 1009 (2,1%) 27 / 1026 (2,6%) 0,79 [0,45;1,39]  
    cardiovascular events 111 / 1009 (11,0%) 159 / 1026 (15,5%) 0,71 [0,57;0,89]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Non fatal MI 3,96% 5,95% -19,8‰
    Cardiovascular death 5,25% 6,92% -16,7‰
    Non vascular death 1,78% 1,07% 7,1‰
    Non fatal stroke 2,08% 2,63% -5,5‰
    cardiovascular events 11,00% 15,50% -45,0‰

    Meta-analysis of all similar trials:

    antiplatelets drug in cardiovascular prevention for secondary prevention in patients with CAD

    antithrombotics in stable angina for all type of patient

    death and events prevention in coronary artery disease for all type of patients



    Reference(s)

    Trials register # NA
    • Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.. Lancet 1992;340:1421-5
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100